{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T18:50:33Z","timestamp":1648752633098},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s00108-006-1681-0","type":"journal-article","created":{"date-parts":[[2006,7,7]],"date-time":"2006-07-07T04:14:10Z","timestamp":1152245650000},"page":"953-959","source":"Crossref","is-referenced-by-count":4,"title":["Moderne pharmakologische Aspekte der Therapie des Aldosteronismus"],"prefix":"10.1007","volume":"47","author":[{"given":"M.","family":"Quinkler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1681_CR1","first-page":"3","volume":"45","author":"Conn","year":"1955","unstructured":"Conn JW (1955) Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45: 3\u201317","journal-title":"J Lab Clin Med"},{"key":"1681_CR2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00004872-200103000-00002","volume":"19","author":"Stowasser","year":"2001","unstructured":"Stowasser M (2001) Primary aldosteronism: revival of a syndrome. J Hypertens 19: 363\u2013366","journal-title":"J Hypertens"},{"key":"1681_CR3","first-page":"1863","volume":"85","author":"Fardella","year":"2000","unstructured":"Fardella CE, Mosso L, Gomez-Sanchez C et al. (2000) Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85: 1863\u20131867","journal-title":"J Clin Endocrinol Metab"},{"key":"1681_CR4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.2003-031337","volume":"89","author":"Mulatero","year":"2004","unstructured":"Mulatero P, Stowasser M, Loh KC et al. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89: 1045\u20131050","journal-title":"J Clin Endocrinol Metab"},{"key":"1681_CR5","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1210\/jc.2003-032179","volume":"89","author":"Olivieri","year":"2004","unstructured":"Olivieri O, Ciacciarelli A, Signorelli D et al. (2004) Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 89: 4221\u20134226","journal-title":"J Clin Endocrinol Metab"},{"key":"1681_CR6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00268-001-0033-4","volume":"25","author":"Gordon","year":"2001","unstructured":"Gordon RD, Stowasser M, Rutherford JC (2001) Primary aldosteronism: are we diagnosing and operating on too few patients? World J Surg 25: 941\u2013947","journal-title":"World J Surg"},{"key":"1681_CR7","first-page":"2854","volume":"85","author":"Loh","year":"2000","unstructured":"Loh KC, Koay ES, Khaw MC et al. (2000) Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85: 2854\u20132859","journal-title":"J Clin Endocrinol Metab"},{"key":"1681_CR8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(05)74868-6","volume":"353","author":"Lim","year":"1999","unstructured":"Lim PO, Rodgers P, Cardale K et al. (1999) Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353: 40","journal-title":"Lancet"},{"key":"1681_CR9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00059-003-2507-7","volume":"28","author":"Seiler","year":"2003","unstructured":"Seiler L, Reincke M (2003) The aldosterone to renin ratio in secondary hypertension. Herz 28: 686\u2013691","journal-title":"Herz"},{"key":"1681_CR10","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1210\/en.2003-0279","volume":"144","author":"Young","year":"2003","unstructured":"Young WF (2003) Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 144: 2208\u20132213","journal-title":"Endocrinology"},{"key":"1681_CR11","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA et al. (2002) Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40: 892\u2013896","journal-title":"Hypertension"},{"key":"1681_CR12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","volume":"348","author":"Wing","year":"2003","unstructured":"Wing LM, Reid CM, Ryan P et al. (2003) A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583\u2013592","journal-title":"N Engl J Med"},{"key":"1681_CR13","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","volume":"283","author":"ALLHAT","year":"2000","unstructured":"ALLHAT Collaborative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283: 1967\u20131975","journal-title":"JAMA"},{"key":"1681_CR14","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","volume":"22","author":"Eide","year":"2004","unstructured":"Eide IK, Torjesen PA, Drolsum A et al. (2004) Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 22: 2217\u20132226","journal-title":"J Hypertens"},{"key":"1681_CR15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","volume":"42","author":"Mosso","year":"2003","unstructured":"Mosso L, Carvajal C, Gonzalez A et al. (2003) Primary aldosteronism and hypertensive disease. Hypertension 42: 161\u2013165","journal-title":"Hypertension"},{"key":"1681_CR16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","volume":"19","author":"Sartori","year":"2006","unstructured":"Sartori M, Calo LA, Mascagna V et al. (2006) Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 19: 373\u2013379","journal-title":"Am J Hypertens"},{"key":"1681_CR17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF et al (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45: 1243\u20131248","journal-title":"J Am Coll Cardiol"},{"key":"1681_CR18","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","volume":"112","author":"Quinkler","year":"2005","unstructured":"Quinkler M, Zehnder D, Eardley KS et al. (2005) Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 112: 1435\u20131443","journal-title":"Circulation"},{"key":"1681_CR19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.mce.2003.10.054","volume":"217","author":"Funder","year":"2004","unstructured":"Funder JW (2004) Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol 217: 263\u2013269","journal-title":"Mol Cell Endocrinol"},{"key":"1681_CR20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.steroids.2005.02.004","volume":"70","author":"Mihailidou","year":"2005","unstructured":"Mihailidou AS, Funder JW (2005) Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 70: 347\u2013351","journal-title":"Steroids"},{"key":"1681_CR21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-2002-34588","volume":"110","author":"Quinkler","year":"2002","unstructured":"Quinkler M, Lepenies J, Diederich S (2002) Primary hyperaldosteronism. Exp Clin Endocrinol Diabetes 110: 263\u2013271","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1681_CR22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7326\/0003-4819-135-4-200108210-00010","volume":"135","author":"Sawka","year":"2001","unstructured":"Sawka AM, Young WF, Thompson GB et al. (2001) Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 135: 258\u2013261","journal-title":"Ann Intern Med"},{"key":"1681_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.ju.0000162045.68387.c3","volume":"174","author":"Ishidoya","year":"2005","unstructured":"Ishidoya S, Ito A, Sakai K et al. (2005) Laparoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol 174: 40\u201343","journal-title":"J Urol"},{"key":"1681_CR24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.7326\/0003-4819-130-9-199905040-00017","volume":"130","author":"Bornstein","year":"1999","unstructured":"Bornstein SR, Stratakis CA, Chrousos GP (1999) Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med 130: 759\u2013771","journal-title":"Ann Intern Med"},{"key":"1681_CR25","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJM199812173392507","volume":"339","author":"Ganguly","year":"1998","unstructured":"Ganguly A (1998) Current concepts \u2013 Primary aldosteronism. N Engl J Med 339: 1828\u20131834","journal-title":"N Engl J Med"},{"key":"1681_CR26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0889-8529(05)70283-8","volume":"26","author":"Young","year":"1997","unstructured":"Young WF (1997) Pheochromocytoma and primary aldosteronism: diagnostic approaches. Endocrinol Metab Clin North Am 26: 801\u2013827","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1681_CR27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archsurg.134.6.628","volume":"134","author":"Shen","year":"1999","unstructured":"Shen WT, Lim RC, Siperstein AE et al. (1999) Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Arch Surg 134: 628\u2013631","journal-title":"Arch Surg"},{"key":"1681_CR28","first-page":"1211","volume":"67","author":"Itoh","year":"1991","unstructured":"Itoh N, Kumamoto Y, Akagashi K et al. (1991) Study of the predictive factors of postoperative blood pressure in cases with primary aldosteronism. Nippon Naibunpi Gakkai Zasshi 67: 1211\u20131218","journal-title":"Nippon Naibunpi Gakkai Zasshi"},{"key":"1681_CR29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","volume":"19","author":"Lim","year":"2001","unstructured":"Lim PO, Young WF, MacDonald TM (2001) A review of the medical treatment of primary aldosteronism. J Hypertens 19: 353\u2013361","journal-title":"J Hypertens"},{"key":"1681_CR30","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(98)06102-9","volume":"353","author":"Stewart","year":"1999","unstructured":"Stewart PM (1999) Mineralocorticoid hypertension. Lancet 353: 1341\u20131347","journal-title":"Lancet"},{"key":"1681_CR31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00000658-199608000-00003","volume":"224","author":"Lo","year":"1996","unstructured":"Lo CY, Tam PC, Kung AW et al. (1996) Primary aldosteronism. Results of surgical treatment. Ann Surg 224: 125\u2013130","journal-title":"Ann Surg"},{"key":"1681_CR32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1527-3466.2001.tb00064.x","volume":"19","author":"Delyani","year":"2001","unstructured":"Delyani JA, Rocha R, Cook CS et al. (2001) Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 19: 185\u2013200","journal-title":"Cardiovasc Drug Rev"},{"key":"1681_CR33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0889-8529(18)30425-0","volume":"17","author":"Young","year":"1988","unstructured":"Young WF Jr, Klee GG (1988) Primary aldosteronism. Diagnostic evaluation. Endocrinol Metab Clin North Am 17: 367\u2013395","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1681_CR34","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jcem.85.9.6834","volume":"85","author":"Stowasser","year":"2000","unstructured":"Stowasser M, Bachmann AW, Huggard PR et al. (2000) Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 85: 3313\u20133318","journal-title":"J Clin Endocrinol Metab"},{"key":"1681_CR35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0960-0760(01)00097-8","volume":"78","author":"Stowasser","year":"2001","unstructured":"Stowasser M, Gordon RD (2001) Familial hyperaldosteronism. J Steroid Biochem Mol Biol 78: 215\u2013229","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1681_CR36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0002-8703(78)90132-1","volume":"96","author":"Ferriss","year":"1978","unstructured":"Ferriss JB, Beevers DG, Boddy K et al. (1978) The treatment of low-renin (\u201eprimary\u201c) hyperaldosteronism. Am Heart J 96: 97\u2013109","journal-title":"Am Heart J"},{"key":"1681_CR37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/bmj.2.5816.729","volume":"2","author":"Brown","year":"1972","unstructured":"Brown JJ, Davies DL, Ferriss JB et al. (1972) Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. BMJ 2: 729\u2013734","journal-title":"BMJ"},{"key":"1681_CR38","doi-asserted-by":"crossref","first-page":"V115","DOI":"10.1161\/01.HYP.5.6_Pt_3.V115","volume":"5","author":"Kater","year":"1983","unstructured":"Kater CE, Biglieri EG, Schambelan M, Arteaga E (1983) Studies of impaired aldosterone response to spironolactone-induced renin and potassium elevations in adenomatous but not hyperplastic primary aldosteronism. Hypertension 5: V115\u2013V121","journal-title":"Hypertension"},{"key":"1681_CR39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00000441-197012000-00001","volume":"260","author":"Crane","year":"1970","unstructured":"Crane MG, Harris JJ (1970) Effect of spironolactone in hypertensive patients. Am J Med Sci 260: 311\u2013330","journal-title":"Am J Med Sci"},{"key":"1681_CR40","first-page":"213s","volume":"45","author":"Kremer","year":"1973","unstructured":"Kremer D, Beevers DG, Brown JJ et al. (1973) Spironolactone and amiloride in the treatment of low renin hyperaldosteronism and related syndromes. Clin Sci Mol Med Suppl 45 [Suppl] 1: 213s\u2013218","journal-title":"Clin Sci Mol Med Suppl"},{"key":"1681_CR41","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"Jeunemaitre","year":"1987","unstructured":"Jeunemaitre X, Chatellier G, Kreft-Jais C et al. (1987) Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 60: 820\u2013825","journal-title":"Am J Cardiol"},{"key":"1681_CR42","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA (2003) Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16: 925\u2013930","journal-title":"Am J Hypertens"},{"key":"1681_CR43","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/ndt\/gfk086","volume":"21","author":"Covic","year":"2006","unstructured":"Covic A, Gusbeth-Tatomir P, Goldsmith DJ (2006) Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant 21: 854\u2013858","journal-title":"Nephrol Dial Transplant"},{"key":"1681_CR44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1055\/s-0029-1210710","volume":"90","author":"Horky","year":"1987","unstructured":"Horky K, Widimsky J, Hradec E et al. (1987) Long-term results of surgical and conservative treatment of patients with primary aldosteronism. Exp Clin Endocrinol 90: 337\u2013346","journal-title":"Exp Clin Endocrinol"},{"key":"1681_CR45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709\u2013717","journal-title":"N Engl J Med"},{"key":"1681_CR46","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309\u20131321","journal-title":"N Engl J Med"},{"key":"1681_CR47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D et al. (2002) Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40: 117\u2013123","journal-title":"Hypertension"},{"key":"1681_CR48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ (2002) Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15: 709\u2013716","journal-title":"Am J Hypertens"},{"key":"1681_CR49","first-page":"650","volume":"240","author":"de","year":"1987","unstructured":"de GM, Joss U, Ramjoue HP et al. (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240: 650\u2013656","journal-title":"J Pharmacol Exp Ther"},{"key":"1681_CR50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.1980.42","volume":"27","author":"Hoefnagels","year":"1980","unstructured":"Hoefnagels WH, Drayer JI, Smals AG, Kloppenborg PW (1980) Spironolactone and amiloride in hypertensive patients with and without aldosterone excess. Clin Pharmacol Ther 27: 317\u2013323","journal-title":"Clin Pharmacol Ther"},{"key":"1681_CR51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2265.1977.tb01307.x","volume":"7","author":"Kremer","year":"1977","unstructured":"Kremer D, Boddy K, Brown JJ et al. (1977) Amiloride in the treatment of primary hyperaldosteronism and essential hypertension. Clin Endocrinol (Oxf) 7: 151\u2013157","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1681_CR52","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/clpt.1981.155","volume":"30","author":"Ganguly","year":"1981","unstructured":"Ganguly A, Weinberger MH (1981) Triamterene-thiazide combination: alternative therapy for primary aldosteronism. Clin Pharmacol Ther 30: 246\u2013250","journal-title":"Clin Pharmacol Ther"},{"key":"1681_CR53","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1210\/jcem-47-5-938","volume":"47","author":"Wisgerhof","year":"1978","unstructured":"Wisgerhof M, Carpenter PC, Brown RD (1978) Increased adrenal sensitivity to angiotensin II in idiopathic hyperaldosteronism. J Clin Endocrinol Metab 47: 938\u2013943","journal-title":"J Clin Endocrinol Metab"},{"key":"1681_CR54","first-page":"779","volume":"5","author":"Griffing","year":"1983","unstructured":"Griffing GT, Melby JC (1983) The therapeutic use of a new potassium-sparing diuretic, amiloride, and a converting enzyme inhibitor, MK-421, in preventing hypokalemia associated with primary and secondary hyperaldosteronism. Clin Exp Hypertens A 5: 779\u2013801","journal-title":"Clin Exp Hypertens A"},{"key":"1681_CR55","doi-asserted-by":"crossref","first-page":"289s","DOI":"10.1042\/cs061289s","volume":"Sci","author":"Mantero","year":"1981","unstructured":"Mantero F, Fallo F, Opocher G et al. (1981) Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. Clin Sci (Lond) 61 [Suppl 7]: 289s\u2013293s","journal-title":"Clin"},{"key":"1681_CR56","first-page":"105","volume":"Endocrinol","author":"Atkinson","year":"1981","unstructured":"Atkinson AB, Brown JJ, Davies DL et al. (1981) Combined captopril and spironolactone treatment in Conn\u2019s syndrome with renal impairment and refractory hypertension. Clin Endocrinol (Oxf) 14: 105\u2013108","journal-title":"Clin"},{"key":"1681_CR57","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-60-5-896","volume":"60","author":"Nadler","year":"1985","unstructured":"Nadler JL, Hsueh W, Horton R (1985) Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab 60: 896\u2013899","journal-title":"J Clin Endocrinol Metab"},{"key":"1681_CR58","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/00005344-198812006-00033","volume":"12","author":"Stimpel","year":"1988","unstructured":"Stimpel M, Ivens K, Wambach G, Kaufmann W (1988) Are calcium antagonists helpful in the management of primary aldosteronism? J Cardiovasc Pharmacol 12 [Suppl 6]: S131\u2013S134","journal-title":"J Cardiovasc Pharmacol"},{"key":"1681_CR59","first-page":"1263","volume":"11","author":"Carpene","year":"1989","unstructured":"Carpene G, Rocco S, Opocher G, Mantero F (1989) Acute and chronic effect of nifedipine in primary aldosteronism. Clin Exp Hypertens A 11: 1263\u20131272","journal-title":"Clin Exp Hypertens A"},{"key":"1681_CR60","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF03348177","volume":"10","author":"Opocher","year":"1987","unstructured":"Opocher G, Rocco S, Murgia A, Mantero F (1987) Effect of verapamil on aldosterone secretion in primary aldosteronism. J Endocrinol Invest 10: 491\u2013494","journal-title":"J Endocrinol Invest"},{"key":"1681_CR61","doi-asserted-by":"crossref","first-page":"88S","DOI":"10.1093\/ajh\/1.3.88S","volume":"1","author":"Bursztyn","year":"1988","unstructured":"Bursztyn M, Grossman E, Rosenthal T (1988) The absence of long-term therapeutic effect of calcium channel blockade in the primary aldosteronism of adrenal adenomas. Am J Hypertens 1: 88S\u201390S","journal-title":"Am J Hypertens"},{"key":"1681_CR62","doi-asserted-by":"crossref","first-page":"E42","DOI":"10.1152\/ajpcell.1981.241.1.C42","volume":"241","author":"Schiffrin","year":"1981","unstructured":"Schiffrin EL, Lis M, Gutkowska J, Genest J (1981) Role of Ca2+ in response of adrenal glomerulosa cells to angiotensin II, ACTH, K+, and ouabain. Am J Physiol 241: E42\u2013E46","journal-title":"Am J Physiol"},{"key":"1681_CR63","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/01.HYP.7.1.90","volume":"7","author":"Bravo","year":"1985","unstructured":"Bravo EL, Tarazi RC, Dustan HP, Fouad FM (1985) The sympathetic nervous system and hypertension in primary aldosteronism. Hypertension 7: 90\u201396","journal-title":"Hypertension"},{"key":"1681_CR64","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF01717327","volume":"67","author":"Stimpel","year":"1989","unstructured":"Stimpel M, Ivens K, Volkmann HP et al. (1989) Therapeutic value of calcium antagonists in autonomous hyperaldosteronism. Klin Wochenschr 67: 248\u2013252","journal-title":"Klin Wochenschr"},{"key":"1681_CR65","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000173956","volume":"72","author":"Winterberg","year":"1985","unstructured":"Winterberg B, Vetter W, Groth H et al. (1985) Primary aldosteronism: treatment with trilostane. Cardiology 72 (Suppl 1): 117\u2013121","journal-title":"Cardiology"},{"key":"1681_CR66","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF01715766","volume":"65","author":"Tenschert","year":"1987","unstructured":"Tenschert W, Maurer R, Vetter H, Vetter W (1987) Primary aldosteronism by carcinoma of the adrenal cortex. Klin Wochenschr 65: 428\u2013432","journal-title":"Klin Wochenschr"},{"key":"1681_CR67","first-page":"clinical","volume":"carcinoma","author":"Allolio","year":"2006","unstructured":"Allolio B, Fassnacht M (2006) Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab (in press)","journal-title":"Adrenocortical"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-006-1681-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-006-1681-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-006-1681-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:11:37Z","timestamp":1558584697000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-006-1681-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["1681"],"URL":"https:\/\/doi.org\/10.1007\/s00108-006-1681-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}